Abstract
The increased use of abdominal imaging techniques for a variety of indications has contributed to more-frequent detection of renal cell carcinoma (RCC). Ultrasonography has been used to characterize the solid versus cystic nature of renal masses. This modality has limitations, however, in further characterization of solid tumors and in staging of malignancy, although contrast-enhanced ultrasonography has shown promise. Cross-sectional imaging with multiplanar reconstruction capability via CT or MRI has become the standard-bearer in the diagnosis, staging and surveillance of renal cancers. The use of specific protocols and the exploitation of different imaging characteristics of RCC subtypes, including variations in contrast agent timing, MRI weighting and digital subtraction, have contributed to this diagnostic capability. Cystic renal masses are a special case, evaluation of which can require multiple imaging modalities. Rigorous evaluation of these lesions can provide information that is crucial to prediction of the likelihood of malignancy. Such imaging is not without risk, however, as radiation from frequent CT imaging has been implicated in the development of secondary malignancies, and contrast agents for CT and MRI can pose risks, particularly in patients with compromised renal function.
Key Points
-
CT is considered the gold standard for the evaluation of a suspicious renal mass; protocols must involve pre-contrast images as well as images obtained at multiple time points after contrast administration
-
CT is also an excellent staging modality that can assess lymphadenopathy, metastatic disease, the risk of adrenal gland involvement and response to systemic therapy
-
Ultrasonography is rarely used alone in the evaluation of a solid renal mass; contrast-enhanced ultrasonography is not yet approved in the USA but might show vascularity of lesions without radiation
-
MRI is an excellent modality that does not employ ionizing radiation, and can aid in the differentiation of benign and malignant lesions; it is also helpful in the evaluation of a vascular tumor thrombus
-
Cystic renal masses require special attention and classification to determine the likelihood of malignancy; MRI is emerging as a useful tool in certain situations to differentiate benign from malignant cysts
-
Assessing response to minimally invasive therapy and systemic treatment with agents such as tyrosine kinase inhibitors is important, with CT currently the most utilized modality, although MRI is a reasonable alternative
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Horner, M. J. et al. SEER Cancer Statistics Review, 1975–2006, National Cancer Institute. Bethesda, MD, [online] (2009).
Gill, I. S., Aron, M., Gervais, D. A. & Jewett, M. A. Clinical practice. Small renal mass. N. Engl. J. Med. 362, 624–634 (2010).
Volpe, A. et al. The natural history of incidentally detected small renal masses. Cancer 100, 738–745 (2004).
Cooperberg, M. R. et al. Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004. J. Urol. 179, 2131–2135 (2008).
Frank, I. et al. Solid renal tumors: an analysis of pathological features related to tumor size. J. Urol. 170, 2217–2220 (2003).
Bach, A. M. & Zhang, J. Contemporary radiologic imaging of renal cortical tumors. Urol. Clin. North Am. 35, 593–604 (2008).
Lane, B. R. et al. Renal mass biopsy—a renaissance? J. Urol. 179, 20–27 (2008).
Silver, D. A., Morash, C., Brenner, P., Campbell, S. & Russo, P. Pathologic findings at the time of nephrectomy for renal mass. Ann. Surg. Oncol. 4, 570–574 (1997).
Schlomer, B., Figenshau, R. S., Yan, Y. & Bhayani, S. B. How does the radiographic size of a renal mass compare with the pathologic size? Urology 68, 292–295 (2006).
Thompson, R. H. et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J. Urol. 181, 2033–2036 (2009).
Campbell, S. C. et al. Guideline for management of the clinical T1 renal mass. J. Urol. 182, 1271–1279 (2009).
Ljungberg, B. et al. Guidelines on Renal Cell Carcinoma (European Association of Urology, 2009).
Bluth, E. I. et al. Indeterminate renal masses. American College of Radiology. ACR Appropriateness Criteria. Radiology 215 (Suppl.), 747–752 (2000).
Choyke, P. L. et al. Renal cell carcinoma staging. American College of Radiology. ACR Appropriateness Criteria. Radiology 215 (Suppl.), 721–725 (2000).
Kopka, L. et al. Dual-phase helical CT of the kidney: value of the corticomedullary and nephrographic phase for evaluation of renal lesions and preoperative staging of renal cell carcinoma. AJR Am. J. Roentgenol. 169, 1573–1578 (1997).
Yuh, B. I. & Cohan, R. H. Different phases of renal enhancement: role in detecting and characterizing renal masses during helical CT. AJR Am. J. Roentgenol. 173, 747–755 (1999).
Ng, C. S. et al. Renal cell carcinoma: diagnosis, staging, and surveillance. AJR Am. J. Roentgenol. 191, 1220–1232 (2008).
Silverman, S. G., Leyendecker, J. R. & Amis, E. S. Jr. What is the current role of CT urography and MR urography in the evaluation of the urinary tract? Radiology 250, 309–323 (2009).
Bosniak, M. A. The current radiological approach to renal cysts. Radiology 158, 1–10 (1986).
Israel, G. M. & Bosniak, M. A. How I do it: evaluating renal masses. Radiology 236, 441–450 (2005).
Siegel, C. L., Fisher, A. J. & Bennett, H. F. Interobserver variability in determining enhancement of renal masses on helical CT. AJR Am. J. Roentgenol. 172, 1207–1212 (1999).
Israel, G. M. & Bosniak, M. A. Pitfalls in renal mass evaluation and how to avoid them. Radiographics 28, 1325–1338 (2008).
Wang, Z. J. et al. Renal cyst pseudoenhancement at multidetector CT: what are the effects of number of detectors and peak tube voltage? Radiology 248, 910–916 (2008).
Bosniak, M. A. Angiomyolipoma (hamartoma) of the kidney: a preoperative diagnosis is possible in virtually every case. Urol. Radiol. 3, 135–142 (1981).
Simpfendorfer, C. et al. Angiomyolipoma with minimal fat on MDCT: can counts of negative-attenuation pixels aid diagnosis? AJR Am. J. Roentgenol. 192, 438–443 (2009).
Kim, J. K., Park, S. Y., Shon, J. H. & Cho, K. S. Angiomyolipoma with minimal fat: differentiation from renal cell carcinoma at biphasic helical CT. Radiology 230, 677–684 (2004).
Choudhary, S., Rajesh, A., Mayer, N. J., Mulcahy, K. A. & Haroon, A. Renal oncocytoma: CT features cannot reliably distinguish oncocytoma from other renal neoplasms. Clin. Radiol. 64, 517–522 (2009).
Prasad, S. R., Surabhi, V. R., Menias, C. O., Raut, A. A. & Chintapalli, K. N. Benign renal neoplasms in adults: cross-sectional imaging findings. AJR Am. J. Roentgenol. 190, 158–164 (2008).
Kim, J. I., Cho, J. Y., Moon, K. C., Lee, H. J. & Kim, S. H. Segmental enhancement inversion at biphasic multidetector CT: characteristic finding of small renal oncocytoma. Radiology 252, 441–448 (2009).
Bastide, C., Rambeaud, J. J., Bach, A. M. & Russo, P. Metanephric adenoma of the kidney: clinical and radiological study of nine cases. BJU Int. 103, 1544–1548 (2009).
Sheir, K. Z., El-Azab, M., Mosbah, A., El-Baz, M. & Shaaban, A. A. Differentiation of renal cell carcinoma subtypes by multislice computerized tomography. J. Urol. 174, 451–455 (2005).
Zhang, J. et al. Solid renal cortical tumors: differentiation with CT. Radiology 244, 494–504 (2007).
Johnson, C. D., Dunnick, N. R., Cohan, R. H. & Illescas, F. F. Renal adenocarcinoma: CT staging of 100 tumors. AJR Am. J. Roentgenol. 148, 59–63 (1987).
Reznek, R. H. CT/MRI in staging renal cell carcinoma. Cancer Imaging 4, S25–S32 (2004).
Guzzo, T., Pierorazio, P., Schaeffer, E., Fishman, E. & Allaf, M. The accuracy of multidetector computerized tomography for evaluating tumor thrombus in patients with renal cell carcinoma. J. Urol. 181, 486–490 (2009).
Hallscheidt, P. et al. Preoperative staging of renal cell carcinoma with inferior vena cava thrombus using multidetector CT and MRI: prospective study with histopathological correlation. J. Comput. Assist. Tomogr. 29, 64–68 (2005).
Lawrentschuk, N., Gani, J., Riordan, R., Esler, S. & Bolton, D. M. Multidetector computed tomography vs magnetic resonance imaging for defining the upper limit of tumour thrombus in renal cell carcinoma: a study and review. BJU Int. 96, 291–295 (2005).
Robson, C. J., Churchill, B. M. & Anderson, W. The results of radical nephrectomy for renal cell carcinoma. J. Urol. 101, 297–301 (1969).
Tsui, K. H. et al. Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies. J. Urol. 163, 437–441 (2000).
O'Malley, R. L., Godoy, G., Kanofsky, J. A. & Taneja, S. S. The necessity of adrenalectomy at the time of radical nephrectomy: a systematic review. J. Urol. 181, 2009–2017 (2009).
Studer, U. E. et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J. Urol. 144, 243–245 (1990).
Blom, J. H. et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur. Urol. 55, 28–34 (2009).
Fazel, R. et al. Exposure to low-dose ionizing radiation from medical imaging procedures. N. Engl. J. Med. 361, 849–857 (2009).
Hall, E. J. & Brenner, D. J. Cancer risks from diagnostic radiology. Br. J. Radiol. 81, 362–378 (2008).
Martin, D. R. et al. Nephrogenic systemic fibrosis versus contrast-induced nephropathy: risks and benefits of contrast-enhanced MR and CT in renally impaired patients. J. Magn. Reson. Imaging 30, 1350–1356 (2009).
Goldenberg, I. & Matetzky, S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ 172, 1461–1471 (2005).
Probert, J. L., Glew, D. & Gillatt, D. A. Magnetic resonance imaging in urology. BJU Int. 83, 201–214 (1999).
Tello, R. et al. MR imaging of renal masses interpreted on CT to be suspicious. AJR Am. J. Roentgenol. 174, 1017–1022 (2000).
Eilenberg, S., Brown, J., Lee, J., Heiken, J. & Mirowitz, S. Evaluation of renal masses with contrast-enhanced rapid acquisition spin echo MR imaging. Magn. Reson. Imaging 11, 7–16 (1993).
Silverman, S. G., Israel, G. M., Herts, B. R. & Richie, J. P. Management of the incidental renal mass. Radiology 249, 16–31 (2008).
Kim, S. et al. T1 hyperintense renal lesions: characterization with diffusion-weighted MR imaging versus contrast-enhanced MR imaging. Radiology 251, 796–807 (2009).
Ho, V., Allen, S., Hood, M. & Choyke, P. Renal masses: quantitative assessment of enhancement with dynamic MR imaging. Radiology 224, 695–700 (2002).
Hecht, E. et al. Renal masses: quantitative analysis of enhancement with signal intensity measurements versus qualitative analysis of enhancement with image subtraction for diagnosing malignancy at MR imaging. Radiology 232, 373–378 (2004).
Kim, J. et al. Renal angiomyolipoma with minimal fat: differentiation from other neoplasms at double-echo chemical shift FLASH MR imaging. Radiology 239, 174–180 (2006).
Garin, J. et al. CT and MRI in fat-containing papillary renal cell carcinoma. Br. J. Radiol. 80, e193–e195 (2007).
Roy, C. et al. Renal cell carcinoma with a fatty component mimicking angiomyolipoma on CT. Br. J. Radiol. 71, 977–979 (1998).
Prasad, S., Surabhi, V., Menias, C., Raut, A. & Chintapalli, K. Benign renal neoplasms in adults: cross-sectional imaging findings. AJR Am. J. Roentgenol. 190, 158–164 (2008).
Prince, M. R., Zhang, H. L., Roditi, G. H., Leiner, T. & Kucharczyk, W. Risk factors for NSF: a literature review. J. Magn. Reson. Imaging 30, 1298–1308 (2009).
Agarwal, R. et al. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol. Dial. Transplant. 24, 856–863 (2009).
Mayr, M., Burkhalter, F. & Bongartz, G. Nephrogenic systemic fibrosis: clinical spectrum of disease. J. Magn. Reson. Imaging 30, 1289–1297 (2009).
Sun, M. et al. Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings. Radiology 250, 793–802 (2009).
Oliva, M. R. et al. Renal cell carcinoma: t1 and t2 signal intensity characteristics of papillary and clear cell types correlated with pathology. AJR Am. J. Roentgenol. 192, 1524–1530 (2009).
Shinmoto, H. et al. Small renal cell carcinoma: MRI with pathologic correlation. J. Magn. Reson. Imaging 8, 690–694 (1998).
Pedrosa, I. et al. MR classification of renal masses with pathologic correlation. Eur. Radiol. 18, 365–375 (2008).
Roy, C. S. et al. Significance of the pseudocapsule on MRI of renal neoplasms and its potential application for local staging: a retrospective study. AJR Am. J. Roentgenol. 184, 113–120 (2005).
Oto, A., Herts, B. R., Remer, E. M. & Novick, A. C. Inferior vena cava tumor thrombus in renal cell carcinoma: staging by MR imaging and impact on surgical treatment. AJR Am. J. Roentgenol. 171, 1619–1624 (1998).
Kallman, D. A. et al. Renal vein and inferior vena cava tumor thrombus in renal cell carcinoma: CT, US, MRI and venacavography. J. Comput. Assist. Tomogr. 16, 240–247 (1992).
Laissy, J. et al. Renal carcinoma: diagnosis of venous invasion with Gd-enhanced MR venography. Eur. Radiol. 10, 1138–1143 (2000).
Aslam Sohaib, S. et al. Assessment of tumor invasion of the vena caval wall in renal cell carcinoma cases by magnetic resonance imaging. J. Urol. 167, 1271–1275 (2002).
Jamis-Dow, C. A. et al. Small (< or = 3-cm) renal masses: detection with CT versus US and pathologic correlation. Radiology 198, 785–788 (1996).
Bos, S. D. & Mensink, H. J. Can duplex Doppler ultrasound replace computerized tomography in staging patients with renal cell carcinoma? Scand. J. Urol. Nephrol. 32, 87–91 (1998).
Frohmüller, H. G., Grups, J. W. & Heller, V. Comparative value of ultrasonography, computerized tomography, angiography and excretory urography in the staging of renal cell carcinoma. J. Urol. 138, 482–484 (1987).
Setola, S. V., Catalano, O., Sandomenico, F. & Siani, A. Contrast-enhanced sonography of the kidney. Abdom. Imaging 32, 21–28 (2007).
Wilson, S. R., Greenbaum, L. D. & Goldberg, B. B. Contrast-enhanced ultrasound: what is the evidence and what are the obstacles? AJR Am. J. Roentgenol. 193, 55–60 (2009).
Tamai, H. et al. Contrast-enhanced ultrasonography in the diagnosis of solid renal tumors. J. Ultrasound Med. 24, 1635–1640 (2005).
Fan, L., Lianfang, D., Jinfang, X., Yijin, S. & Ying, W. Diagnostic efficacy of contrast-enhanced ultrasonography in solid renal parenchymal lesions with maximum diameters of 5 cm. J. Ultrasound Med. 27, 875–885 (2008).
Park, B. K. et al. Assessment of cystic renal masses based on Bosniak classification: comparison of CT and contrast-enhanced US. Eur. J. Radiol. 61, 310–314 (2007).
Piscaglia, F. & Bolondi, L. The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med. Biol. 32, 1369–1375 (2006).
ter Haar, G. Safety and bio-effects of ultrasound contrast agents. Med. Biol. Eng. Comput. 47, 893–900 (2009).
Carrim, Z. I. & Murchison, J. T. The prevalence of simple renal and hepatic cysts detected by spiral computed tomography. Clin. Radiol. 58, 626–629 (2003).
Israel, G. M. & Bosniak, M. A. An update of the Bosniak renal cyst classification system. Urology 66, 484–488 (2005).
Song, C. et al. Differential diagnosis of complex cystic renal mass using multiphase computerized tomography. J. Urol. 181, 2446–2450 (2009).
Bach, A. & Zhang, J. Contemporary radiologic imaging of renal cortical tumors. Urol. Clin. North Am. 35, 593–604 (2008).
Israel, G. & Bosniak, M. MR imaging of cystic renal masses. Magn. Reson. Imaging Clin. N. Am. 12, 403–412 (2004).
Israel, G., Hindman, N. & Bosniak, M. Evaluation of cystic renal masses: comparison of CT and MR imaging by using the Bosniak classification system. Radiology 231, 365–371 (2004).
Sandrasegaran, K. et al. Usefulness of diffusion-weighted imaging in the evaluation of renal masses. AJR Am. J. Roentgenol. 194, 438–445 (2010).
Crispen, P. L. et al. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer 115, 2844–2852 (2009).
Sowery, R. D. & Siemens, D. R. Growth characteristics of renal cortical tumors in patients managed by watchful waiting. Can. J. Urol. 11, 2407–2410 (2004).
The American College of Radiology ACR Appropriateness Criteria®. Clinical Condition: Follow up of Renal Cell Carcinoma [online], (2009).
Gervais, D. A., McGovern, F. J., Arellano, R. S., McDougal, W. S. & Mueller, P. R. Radiofrequency ablation of renal cell carcinoma: part 1, Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR Am. J. Roentgenol. 185, 64–71 (2005).
Wile, G. E., Leyendecker, J. R., Krehbiel, K. A., Dyer, R. B. & Zagoria, R. J. CT and MR imaging after imaging-guided thermal ablation of renal neoplasms. Radiographics 27, 325–339 (2007).
Davenport, M. S. et al. MRI and CT characteristics of successfully ablated renal masses: imaging surveillance after radiofrequency ablation. AJR Am. J. Roentgenol. 192, 1571–1578 (2009).
Kawamoto, S., Permpongkosol, S., Bluemke, D. A., Fishman, E. K. & Solomon, S. B. Sequential changes after radiofrequency ablation and cryoablation of renal neoplasms: role of CT and MR imaging. Radiographics 27, 343–355 (2007).
Matsumoto, E. D. et al. The radiographic evolution of radio frequency ablated renal tumors. J. Urol. 172, 45–48 (2004).
Bensalah, K., Zeltser, I., Tuncel, A., Cadeddu, J. & Lotan, Y. Evaluation of costs and morbidity associated with laparoscopic radiofrequency ablation and laparoscopic partial nephrectomy for treating small renal tumours. BJU Int. 101, 467–471 (2008).
Clark, T. W. et al. Reporting standards for percutaneous thermal ablation of renal cell carcinoma. J. Vasc. Interv. Radiol. 20, S409–S416 (2009).
Kassouf, W. et al. Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma. Can. Urol. Assoc. J. 3, 73–76 (2009).
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology—Kidney Cancer [online], (2009).
Ljungberg, B. et al. Renal cell carcinoma guideline. Eur. Urol. 51, 1502–1510 (2007).
Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007).
Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271–2281 (2007).
Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584–3590 (2009).
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
Maksimovic, O. et al. Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment. AJR Am. J. Roentgenol. 194, 5–14 (2010).
Smith, A. D., Lieber, M. L. & Shah, S. N. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am. J. Roentgenol. 194, 157–165 (2010).
US National Institutes of Health. A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma—University of Toronto. http://clinicaltrials.gov/ct2/show/NCT00480935 (2010).
O'Connor, J. P., Jackson, A., Parker, G. J. & Jayson, G. C. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br. J. Cancer 96, 189–195 (2007).
Lamuraglia, M. et al. Clinical relevance of contrast-enhanced ultrasound in monitoring anti-angiogenic therapy of cancer: current status and perspectives. Crit. Rev. Oncol. Hematol. 73, 202–212 (2010).
Lamuraglia, M. et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur. J. Cancer 42, 2472–2479 (2006).
Willmann, J. K. et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 246, 508–518 (2008).
Lawrentschuk, N., Davis, I. D., Bolton, D. M. & Scott, A. M. Functional imaging of renal cell carcinoma. Nat. Rev. Urol. doi:10.1038/nrurol.2010.40.
Warren, K. S. & McFarlane, J. The Bosniak classification of renal cystic masses. BJU Int. 95, 939–942 (2005).
Acknowledgements
Charles P. Vega, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the MedscapeCME-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Leveridge, M., Bostrom, P., Koulouris, G. et al. Imaging renal cell carcinoma with ultrasonography, CT and MRI. Nat Rev Urol 7, 311–325 (2010). https://doi.org/10.1038/nrurol.2010.63
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2010.63
This article is cited by
-
A serum panel of three microRNAs may serve as possible biomarkers for kidney renal clear cell carcinoma
Cancer Cell International (2024)
-
CD56 polysialylation promotes the tumorigenesis and progression via the Hedgehog and Wnt/β-catenin signaling pathways in clear cell renal cell carcinoma
Cancer Cell International (2023)
-
Comparative diagnostic performance of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging for differentiating clear cell and non-clear cell renal cell carcinoma
European Radiology (2023)
-
Distinguishing common renal cell carcinomas from benign renal tumors based on machine learning: comparing various CT imaging phases, slices, tumor sizes, and ROI segmentation strategies
European Radiology (2023)
-
Moderne Schnittbildgebung für urologische Erkrankungen
Der Urologe (2022)